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Background: Panax Notoginseng Saponins (PNS) is the major class of active constituents of notoginseng, a natural
product extensively used as a therapeutic agent in China. Tumor when accompanied by cardiovascular disorders
poses a greater challenge for clinical management given the paradoxical involvement of angiogenesis, therefore
gaining increased research attention. This study aim to investigate effects of PNS and its activity components in the
mouse model of tumor complicated with myocardial ischemia.
Methods: Tumor complexed with myocardial ischemia mouse model was first established, which was followed by
histological and immunohistochemistry examination to assess the effect of indicated treatments on tumor, myocardial
ischemia and tissue specific angiogenesis. MicroRNA (miRNA) profiling was further carried out to identify potential
miRNA regulators that might mechanistically underline the therapeutic effects of PNS in this complex model.
Results: PNS and its major activity components Rg1, Rb1 and R1 suppressed tumor growth and simultaneously
attenuated myocardial ischemia. PNS treatment led to decreased expression of CD34 and vWF in tumor and increased
expression of these vascular markers in heart. PNS treatment resulted in reduced expression of miR-18a in tumor and
upregulated expression of miR-18a in heart.
Conclusions: Our data demonstrated for the first time that PNS exerts tissue specific regulatory effects on
angiogenesis in part through modulating the expression of miR-18a, which could be responsible for its bidirectional
effect on complex disease conditions where paradoxical angiogenesis is implicated. Therefore, our study provides
experimental evidence warranting evaluation of PNS and related bioactive component as a rational therapy for
complex disease conditions including co-manifestation of cancer and ischemic cardiovascular disease.
Keywords: Myocardial ischemia, Tumor, Angiogenesis, PNS, Bidirectional regulation, miR-18aBackground
Cardiovascular disease and cancer are independent lead-
ing causes of morbidity and mortality worldwide, ser-
iously threatening human health and quality of life. With
increase in the incidence of both cardiovascular disease,
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unless otherwise stated.patients simultaneously laden with cardiovascular disease
and malignant tumor is increased, and these complex
pathological conditions pose greater challenge for clinical
treatment. Moreover, anti-cancer agents or chemother-
apies cause cardiovascular side effects including myocar-
dial ischemia. Therefore, it remains as a research focus to
develop therapies that present effective management of
both cardiovascular disease and tumor when both condi-
tions are coexistent in a particular patient.
It is a well-established concept that angiogenesis plays
crucial roles in the pathogenesis of various diseases in-
cluding tumor growth and progression and myocardial
ischemia [1]. Enhanced or excessive angiogenesis isd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sufficient angiogenesis is one of the essential patho-
logical features implicated in myocardial ischemia.
Therefore, anti-angiogenic therapy has been considered
as a new modality for tumor treatment. On the other
hand, treatment promoting angiogenesis is recognized
as an important strategy to enhance the clinical man-
agement of myocardial ischemia [2].
Notoginseng is a one of the most extensively used
medicinal herb that has a long history of clinical
utilization in treating various diseases either by itself or
in combination with other natural products in Trad-
itional Chinese Medicine (TCM) [3]. The major active
components of notoginseng are panax notoginseng sa-
ponins (PNS), which consist of more than 30 different
types of saponins, among which ginsenoside Rg1, Rb1
are found in high content and notoginsenoside R1 a
component unique to notoginseng [4]. PNS has been
widely adopted as a therapeutic agent for treating car-
diovascular diseases in clinic under the guidance of
TCM theory [5]. Experimental evidences have been pre-
sented indicating that the cardiovascular benefits of
PNS are mediated through diverse mechanisms includ-
ing alleviating oxidative stress, promoting angiogenesis,
modifying vasomotor function, reducing platelet adhe-
sion, modulating ion channels, altering autonomic
neurotransmitters release, and improving lipid profiles,
etc [6]. Each component of PNS may exert different
pharmacological effects underlined by varied mecha-
nisms. Independent studies have shown that PNS could
stimulate HUVEC proliferation, increase the numbers
of invaded cells and tube branches and promote
changes in the subintestinal vessels in zebrafish, sup-
porting that PNS are equipped with proangiogenic
functions [7]. Ginsenoside Rg1 has been noted as a
stable proangiogenic agent in that HUVEC prolifera-
tion, migration and tube formation were significantly
enhanced in the presence of Rg1 in vitro, and the dens-
ity of newly formed vessels in the animals receiving Rg1
treatment witnessed significantly increase as well [8].
On the other hand, ginsenoside Rb1 exhibits inhibitory
effects on proliferation and tube-like structure forma-
tion of endothelial cells in vitro [9,10]. Notoginsenoside
R1 instead has been shown to be a promising com-
pound for protecting the heart from septic shock and
has anti-inflammatory effects in mice [11].
Additionally, PNS and its major components exhibit
anticancer activities and have been shown to be effective
against a variety of malignancies, for instance, colorec-
tal, lung, gastric, skin, prostate and liver cancer [12]. It
has been shown that PNS, Rg1, Rb1 or R1 display anti-
proliferative activities in tumor cells [13]. Whether or
not PNS, Rg1, Rb1 or R1 exert anti-angiogenesis effects
in the context of tumor growth and progression remainsto be evaluated. Furthermore, whether PNS, Rg1, Rb1
or R1 could simultaneously exert proangiogenic and
antiangiogenic effect when myocardial ischemia is com-
plexed with tumor is unknown.
To address this, we established the model of lewis
lung carcinoma coupled with myocardial ischemia in
mouse, and investigated the effects of PNS and its
major activity components Rg1, Rb1 or R1 on the
tumor growth and myocardial ischemia in this complex
model. We further evaluated the impact of PNS, Rg1,
Rb1 or R1 on the angiogenic events and associated miR
expression in tumor and heart in this complex model.
Our results for the first time demonstrated a bidirec-
tional regulatory effect of PNS on angiogenesis under
complex disease conditions such as tumor coupled with
myocardial ischemia, which may contribute to the sim-
ultaneous effects of PNS on suppressing tumor growth
and alleviating myocardial ischemic injuries. Our data
further suggest that this bidirectional effect of PNS on
angiogenesis in vivo could be achieved through tissue




Panax Notoginseng Saponins (PNS) with a purity of 98%
was obtained from BioAsia International Life Science
Research LTD (Shanghai, China). The structures and
HPLC analysis of the content of ginsenoside Rg1 (Rg1),
ginsenoside Rb1 (Rb1) and notoginsenoside R1 (R1) in
the PNS used for the current study was indicated in our
previous publication [14]. Rg1, Rb1, and R1 with a purity
of 98% were obtained from Shanghai Source Leaf Bio-
logical Technology Co. LTD (Shanghai, China). PNS,
Rg1, Rb1 and R1 were dissolved in phosphate buffer
solution (PBS) and stored at -20°C, and warmed up in
37°C water bath prior to each injection. Isoproterenol
hydrochloride (ISO) was obtained from TOKYO Chem-
ical Industry Co., Ltd.
Animals
C56BL/6J male mice with approximate body weight
(BW) of 20 g were purchased from Shanghai Laboratory
Animal Research Center. The mice were kept under con-
trolled laboratory conditions with temperature at 25 ±
2°C, relative humidity of 60% ± 5%,and a light-dark cycle
of 12 h each. All procedures complied with the standards
for the care and use of animal subjects as stated in the
Guide for the Care and Use of Laboratory Animals (is-
sued by the Ministry of Science and Technology of
China, Beijing). All the procedures were reviewed and ap-
proved by Institutional Animal Care and Use Committee
of Shanghai University of TCM (certificate of approval:
SYXK(Hu) 2006-0001, NO.0069937).
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myocardial ischemia
Murine lewis lung carcinoma (LLC) cell line was obtained
from the American Type Culture Collection (Manassas,
VA, USA). The LLC cells were grown in Dulbecco’s modi-
fied Eagles medium (DMEM) supplemented with 10%
fetal bovine serum. Cells were cultured at 37°C in a 5%
CO2 humidified incubator. Sub-culturing was performed
using standard trypsinization procedures.
To establish tumor growth in the mouse, 1 × 106 LLC
cells were implanted subcutaneously via a 23-gauge needle
in the right inguinal region of each mouse. Solid tumors
were established over a period of 10 days. After 10 days,
the length and width of tumor were measured with ver-
nier caliper. ISO was dissolved in PBS, and was delivered
in the volume of 100 μL at the dose of 10 mg/kg BW
through intraperitoneal injection for 10 consecutive days.
All of the mice were randomly divided into 6 groups (n =
5 per group). Mice served as normal controls received
PBS. Complex model was established by introducing
Lewis lung carcinoma cells and administering ISO as de-
scribed above. PNS treatment was further administered to
the complex model at the dose of 150 mg/kg BW deliv-
ered in the volume of 100 μL via intraperitoneal injection
for 20 days. Similarly, Rg1, Rb1 or R1 was administered to
the complex model at the dose of 50 mg/kg BW, 50 mg/
kg BW and 10 mg/kg, respectively. The choice of dosages
was based upon the results from the preliminary studies,
which had demonstrated an optimal effect of PNS on at-
tenuating myocardial ischemic injuries when administered
at the dose of 150 mg/kg BW. The dose of Rg1, Rb1 and
R1 was calculated and estimated mainly according to the
content of each component in PNS [14] and the afore-
mentioned optimal dose of PNS. Same dose for Rg1 and
Rb1 was adopted in the current study to better compare
the effects of these two major saponins under complex
pathological conditions. At the end of the experimental
period, mice were sacrificed by overdose of anaesthetization
with subcutaneous injection 100 uL 10% chloral hydrate.
Histology and immunohistochemistry
Heart and tumor fixed in 4% paraformaldehyde were
embedded in paraffin and sections were prepared in the
thickness of 5 μm. Serial sections from tumor and left
ventricles were collected and equally spaced sections at
the interval of 10 sections were first examined by
Hematoxylin & eosin (H&E) staining to analyze the
pathological changes, which was followed by Masson’s
trichrome staining and immunohistochemical examina-
tions of the adjacent sections. To examine the expres-
sions of CD34 and von Willebrand factor (vWF) in
heart and tumor tissue sections, immunohistochemistry
(IHC) was performed. Briefly, sections were deparaffi-
nized in xylene and rehydrated through a gradedethanol series. After blocking with 10% normal rabbit
serum in phosphate-buffered saline, the tissue sections
were incubated sequentially with a rabbit anti-mouse
CD34 primary antibodies (Cat#ab81289, Abcam, USA)
for 30 min, followed by incubation with biotin-
conjugated rat anti-rabbit IgG (Solarbio, Shanghai) for
30 min, HRP-Streptavidin (Solarbio, Shanghai) for add-
itional 30 min and the immunoreactivity was developed
using diaminobenzidine (DAB) reagent (Vector Labora-
tories, Burlingame, USA) for 10 min. For vWF IHC,
tissue sections were first incubated with vWF pri-
mary antibodies (Cat#11778-1-AP, Solarbio, Shanghai)
followed by incubation with FITC-conjugated secondary
antibodies (Cat#F7367-1ML, Sigma, USA). Images were
acquired using an upright Leica DM6000B microscope
(Leica Microsystems, Germany).
MicroRNA profiling analysis
Total RNA of tumor samples was isolated using mirVana™
PARIS™ kit (Cat#AM1556, Ambion, USA) following the
manufacturer’s instructions. MicroRNA expression profil-
ing was carried out using SurePrint G3 mouse v16.0
miRNA Array Kit 8×60K (Cat#G4859A, Agilent technolo-
gies, USA), which contained 1023 mouse miRNAs and 57
mouse viral miRNAs as annotated in the Sanger database
miRBase16.0.
Quantitative real time PCR analysis
After isolation of total RNA as described above, reverse
transcription was carried out using miScript Reverse Tran-
scription Kit (Qiagen, USA) and the real time PCR was per-
formed using QuantiTect SYBR Green PCR Master Mix
(Cat#218073, Qiagen, USA) following the manufacturer’s
instruction on Roche LightCycler 480 II. The primers for
PCR are miScript universal primer and mmu-miR-18a
specific primer, 5’-TAAGGTGCATCTAGTGCAGATAG-
3’. All samples were run in triplicates and normalized to the
internal control U6b using primer 5’-ACGCAAATTCGT
GAAGCGTT-3’. The relative expression of miRNA was
calculated with 2-[Ct(microRNA)-Ct(U6b)].
Statistical analysis
Results were expressed as mean ± standard error of
mean (SEM). Variance analysis was used for statistical
comparisons between groups, followed by the student t-
test using SPSS 13.0 Software. Statistical significance was
set at p < 0.05.
Results
PNS or its major activity components inhibited tumor
growth in the complex mouse model
The complex mouse model was established by inoculat-
ing C57BL/6J mouse with LLC cells followed by iso-
proterenol (ISO) administration at the dose of 10 mg/kg
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ISO is a sympathomimetic β-adrenergic receptor agon-
ist and induces infarct like cell death of cardiac muscle.
The animal model of ISO-induced myocardial injury re-
capitulates metabolic and morphological changes occur-
ring during human myocardial infarction, therefore, it is
frequently adopted as a standardized model for evaluat-
ing the cardiac protective effects of pharmacological
agents against myocardial ischemic injury [15-19].
Tumor growth of the complex mice treated with PBS
vehicle or indicated treatments including PNS, Rg1, Rb1
or R1 were monitored and documented. As shown in
Figure 1, tumor volume was progressively increased in
the vehicle-treated complex mice. PNS, Rg1, or R1
treatment exhibited more significant effects on inhibit-
ing tumor growth than that observed from Rb1Figure 1 PNS or its major active components Rg1, Rb1, and R1
inhibited tumor growth in the complex mouse model. A.
Growth curve of the tumor from vehicle-treated complex model
(model), and PNS (150 mg/kg), Rg1 (50 mg/kg), Rb1 (50 mg/kg), R1
(10 mg/kg) treatment, respectively. Tumor volume (TV) (mm3) =
(width2 × length)/2. B. Size of dissected tumor at the termination
of experiment.treatment. The tumor inhibition rates (Table 1) revealed
a marked effect of PNS, Rg1, Rb1, or R1 on inhibiting
tumor growth in the complex model. Note that among
all the compounds examined, PNS showed the most
pronounced effect on tumor inhibition in this complex
mouse model.
PNS or its major activity components alleviated
myocardial ischemia in the complex mouse model
Histological examination of heart was next performed
in vehicle-treated normal mouse controls, vehicle-
treated complex mice and complex mice receiving indi-
cated treatment including PNS, Rg1, Rb1, or R1. As
shown in Figure 2A, in normal controls, left ventricles
were characterized with intact cardiac histology featur-
ing regular organization of myocytes without any sign
of necrosis. In distinct contrast, ISO induced myocar-
dial injuries including necrotic degeneration, granula-
tion as well as inflammatory cell infiltration, which was
invariably observed in vehicle-treated complex mice.
Whereas, milder necrosis and less infiltration of in-
flammatory cells was observed in complex mice treated
with PNS, Rg1, Rb1 and R1, respectively. Myocardial is-
chemia associated fibrotic injury was further evaluated
by Masson’s trichrome staining, a commonly adopted
approach for the detection of collagen fibers in tissue
sections. As shown in Figure 2B, hearts from normal
controls appeared morphologically normal. However,
focal fibrotic areas were readily detected in vehicle-
treated complex mice, which were significantly allevi-
ated in the complex mice treated with PNS, Rg1, Rb1,
and R1, respectively (Table 2).
PNS inhibited tumor angiogenesis, but promoted
angiogenesis in ischemic heart in the complex mouse
model
Results of tumor growth and morphological examina-
tions revealed that PNS and its major active compo-
nents significantly inhibited tumor growth and
meanwhile attenuated myocardial ischemic injuries in
the complex mouse model. Given that angiogenesis is
critically involved in tumor growth and is important for
ischemic heart to recuperate, we went on to assess the
impact of PNS on tumor and myocardial ischemia-
associated angiogenesis in the complex mouse model.
Therefore the expression of CD34 and vWF, molecular
markers of vascular endothelial cell, in tumor and heart
tissue sections was further evaluated by IHC. As shown
in Figure 3A and C, the expressions of CD34 in heart
was significantly increased in vehicle-treated complex
model compared to that from the normal control, pre-
sumably as a result of ischemia-induced angiogenic re-
sponse. An even greater increase in the expression of
CD34 was observed in the complex model treated with
Table 1 Tumor inhibition rate
Group Tumor weight (g) Tumor inhibition rate (%)
Complex model
(n = 6)
0.5923 ± 0.2918 /
PNS (n = 5) 0.1037 ± 0.042 82.48%*
Rg1 (n = 5) 0.1702 ± 0.047 71.26%*
Rb1 (n = 6) 0.3536 ± 0.3395 40.30%*
R1 (n = 6) 0.2718 ± 0.3109 54.11%*
Tumor inhibition rate (%) = (1-average tumor weight in treated mice/average
tumor weight in complex control) × 100%. * p < 0.05 vs. complex control.
Yang et al. BMC Complementary and Alternative Medicine 2014, 14:183 Page 5 of 9
http://www.biomedcentral.com/1472-6882/14/183PNS, suggesting a proangiogenic effect of PNS on
ischemic heart. In distinct contrast, a remarkable re-
duction in the expression of CD34 was observed in tu-
mor sections in PNS-treated complex mice compared
to that from the vehicle-treated complex mice (Figure 3B
and C), suggesting that PNS exert a significant antian-Figure 2 PNS, Rg1, Rb1, and R1 treatment attenuated myocardial isch
performed to examine the histological changes in the hearts. Myocardial n
were evident in the hearts from the vehicle-treated complex mice. PNS, Rg
features in the complex mice. Scale bars indicate 100 μm. B. Masson’s trich
fibrosis in the vehicle-treated complex mice, which was attenuated by PNSgiogenic effect in growing tumor. Similar observations
were made when vWF was examined to monitor the an-
giogenic process. As shown in Figure 3D and F, a mar-
ginal increase in vWF expression was found in the heart
sections in vehicle-treated complex mice compared to
that from normal controls, which was further enhanced
by PNS treatment. Consistently with the result from
CD34 expression analysis, a significant decrease in the
expression of vWF was observed in the tumor sections
of PNS-treated complex mice compared to that from
the vehicle-treated complex mice (Figure 3E and F).
These results demonstrated that PNS treatment led to
enhanced angiogenesis in ischemic hearts whereas sup-
pressed angiogenesis in growing tumor, implying a bi-
directional regulatory action of PNS on angiogenesis
in vivo depending upon the tissue type and pathological
context.emic injuries in the complex mouse model. A. H&E staining was
ecrotic degeneration, granulation and inflammatory cell infiltration
1, Rb1, or R1 treatment significantly attenuated these pathological
rome staining was performed and revealed significant myocardial
, Rg1, Rb1, and R1 treatment, respectively. Scale bars indicate 100 μm.
Table 2 Quantification of Masson’s trichrome staining
Group Relative area of fibrosis (%)
Normal control 1.43 ± 0.35
Complex model 23.17 ± 8.31&
PNS 8.18 ± 3.22*
Rg1 9.64 ± 2.87*
Rb1 8.72 ± 2.13*
R1 10.16 ± 4.31*
&p < 0.05 vs. normal control, *p < 0.05 vs. the complex model.
Figure 3 The expression of CD34 and vWF in the heart and tumor in
heart A. and tumor B. for the expression of CD34 was examined. CD34-pos
hematoxylin. C. Quantification of CD34 positive staining in the heart and tu
tumor E. for the expression of vWF was also examined. vWF -positive cells ap
of vWF positive staining in the heart and tumor, respectively. Scale bars indic
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PNS inhibited tumor growth and attenuated the devel-
opment of myocardial ischemic injuries in the complex
mice, which could be attributed to its bidirectional ac-
tion in modulating angiogenesis in the growing tumor
and ischemic heart, respectively. To further probe the
molecular mechanism that could be responsible for this
bidirectional action of PNS in the process of angiogen-
esis, miR profiling in tumor samples was examined by
microarray to uncover potential miRs affected by PNS
treatment. Interesting, miR-18a, proangiogenic in its
known function, was found to be differentially expressedthe complex mouse model. Immunohistochemistry examination of
itive cells appeared in brown. Nuclei were stained as blue by
mor, respectively. Immunohistochemistry examination of heart D. and
peared in green. Nuclei were stained as blue by DAPI. F. Quantification
ate 50 μm. *p < 0.05, compared to the vehicle-treated complex model.
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that from the vehicle-treated complex mice (p < 0.05).
Further validation of miR-18a expression was carried
out by real time PCR analysis and a significant reduction
in its expression in tumors from PNS-treated complex
mice was confirmed compared to that from vehicle-
treated controls (Figure 4). The expression of miR-18a
was also examined in the hearts. The result showed that
compared to that from the hearts in the vehicle-treated
normal controls, the expression of miR-18a in the hearts
was mildly down-regulated in the vehicle-treated com-
plex mice, however, PNS treatment led to a significant
increase in miR-18a expression compared to that from
the vehicle-treated complex mice (p < 0.05). These re-
sults suggested that PNS regulated the expression of
miR-18a in a tissue specific and bidirectional manner.
Discussion
Our current study provided experimental evidence dem-
onstrating that PNS and its major bioactive components
Rg1, Rb1 or R1 exert a significant therapeutic effect on a
complex disease condition featuring concomitant presen-
tation of lewis lung carcinoma and myocardial ischemia
in mouse, in which the effective therapies are confounded
by paradoxical angiogenic processes in growing tumor
and ischemic heart, respectively. PNS was further re-
vealed to be able to inhibit tumor angiogenesis and in the
meantime, promote myocardial ischemia-induced angio-
genesis in this complex mouse model. Moreover, this bi-
directional effect of PNS on tissue specific and context
dependent angiogenesis is in part mediated through miR-
18a expression regulation.
Therapeutic strategies targeting angiogenesis provide
feasible avenues to cure a variety of diseases such as cancer
and cardiovascular diseases in which aberrant angiogenesisFigure 4 Expression of miR-18a in heart and tumor, respectively.
Real time PCR analyses of the expression of miR-18a in heart
and tumor. *p < 0.05, compared to the vehicle-treated
complex model.plays a central role in the disease development and pro-
gression. The established notion that excessive angiogen-
esis is one of the key processes in the tumor growth and
progression has led to the utilization of antiangiogenic
agents in the treatment of cancer, whereas proangiogenic
therapies have been explored as options to treat cardiovas-
cular diseases given the beneficial significance of enhancing
angiogenesis in post-ischemic hearts. However, neither sin-
gular antiangiogenic nor proangiogenic therapy seems to
be proper for patients laden with tumor and myocardial is-
chemia. Moreover, therapies using monoclonal antibodies
such as bevacizumab, an inhibitor of VEGF receptor, in-
creases the survival of some patients with cancer, but also
increases the risk of adverse cardiovascular effects, includ-
ing hypertension, stroke and myocardial infarction [20]. In
the effort of seeking rational therapies dealing with com-
plex pathological conditions, the attention have been
turned to natural products, given the fact that they most
often are composed of a variety of active components that
enable them to exert therapeutic effects through multiple
cellular and molecular targets and in the case of PNS, may
exhibit differential and bidirectional effects in a tissue and
context dependent fashion [21,22].
In our current study, we identified that PNS have an
ability of modulating angiogenesis with antiangiogenic
activity in tumor and proangiogenic activity in ischemic
heart, possibly through tissue specific regulation of the
expression of miR-18a. miR-18a belongs to miR-17-92
cluster which displays potent proangiogenic activity in
tumor. Studies have revealed significant overexpression
of miR-18a in several types of tumor, including lung can-
cers, gastric cancer and oesophageal squamous cell car-
cinoma [23-25]. Intriguingly, a decreased expression of
miR-18a and increased expression of its angiogenesis in-
hibitors such as connective tissue growth factor (CTGF)
and thrombospondin-1 (TSP-1) were found in relation to
age-related heart failure [26,27]. Therefore, the bidirec-
tional therapeutic action of PNS in tumor complexed
with myocardial ischemia model could be achieved
through tissue specific regulation of the expression of
miR-18a. PNS could accomplish inhibitory effect on
tumor angiogenesis through downregulating the expres-
sion of miR-18a in tumor, whereas in the ischemic heart,
the administration of PNS results in upregulated expres-
sion of miR-18a.
As demonstrated by the current study, when adminis-
tered at the same dose, Rg1 treatment achieved a greater
effect on inhibiting tumor growth compared to that
from the Rb1 treatment, while similar effect of cardio-
protection was observed from both Rg1 and Rb1 treat-
ment. R1 treatment resulted in similar cardioprotection
compared to that from the Rg1 and Rb1 treatment. In
the meantime, R1 treatment led to greater tumor inhib-
ition than that from the Rb1 treatment but this effect of
Yang et al. BMC Complementary and Alternative Medicine 2014, 14:183 Page 8 of 9
http://www.biomedcentral.com/1472-6882/14/183R1 treatment was not as prominent as that from the Rg1
treatment. These results suggest a tissue specific effect of
different saponin contained in PNS. Moreover, it is not-
able that PNS exhibited the most significant effects on
tumor inhibition and cardioprotection when given at a
dose that contained comparable amounts of the Rg1, Rb1
and R1. These results suggest a synergistic effect of dif-
ferent active components on cardioprotection and tumor
inhibition, implying a better therapeutic strategy should
be an integration of bioactive components at an optimal
ratio, which remains to be evaluated in more details in
the future studies.
The differential effects of PNS on tissue specific ex-
pression of miR-18a could be mediated by tissue specific
enrichment and action of its activity components under
a particular pathological condition, which remains to be
further addressed. The downstream gene targets that
could mediate the effects of miR-18a in response to PNS
treatment in tumor and ischemic hearts requires further
investigation. Therefore, the future study would be fo-
cused on analyzing miR-18a expression after administer-
ing the complex mice with each bioactive component of
PNS and various combinations of bioactive components
arranged at different ratios, which will shed light on the
mechanisms of action of each bioactive component of
PNS under complex angiogenic conditions and provide
rationale for further therapeutic development treating
complex disorders implicating complicated angiogenic
events.Conclusions
Taken together, the current study demonstrated for the
first time that PNS and its major activity components
Rg1, Rb1 and R1 effectively suppressed tumor growth
and attenuated myocardial ischemic injuries in the com-
plex mouse model featuring simultaneous presentation of
both disease conditions. These observations provide ex-
perimental evidence supporting that PNS or its major ac-
tivity components Rg1, Rb1 and R1 could be considered
as candidate drugs for further development to manage
complex disease conditions such as cancer combined
with cardiovascular disease. Furthermore, novel mechan-
istic evidence is presented here supporting the notion
that PNS regulate angiogenesis in a bidirectional fashion
through modulating the expression of miR-18a in a tissue
specific and context dependent manner.
Competing interests
The authors declare no conflict of interests.
Authors’ contributions
QY, XW, JC, PW, MX. CJ, LL, BN, LL performed experiments and analyzed
data. WW analyzed data. YC and TZ designed and experiments and analyzed
the data. QY, YC and TZ wrote the manuscript. All authors read and
approved the final manuscript.Acknowledgments
This work was supported by the Program for Professor of Special
Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning
(Y.C and T.Z); Program for Pu Jiang Scholar at Science and Technology
Commission of Shanghai Municipality (11PJ1409000, 13PJ1407800, Y.C and T.
Z); Shu Guang Project supported by Shanghai Municipal Education
Commission and Shanghai Education Development Foundation (13SG42);
National Natural Science Foundation of China (81273960) (T.Z); Funding for
Outstanding Junior Faculties at Shanghai Institutions of Higher Learning
(ZZszy12048) (P.W); Three-year Projects to Promote Traditional Chinese
Medicine, Shanghai (NO. ZYSNXD-CC-ZDYJ050); and Key Disciplines of
Clinical Integrative Medicine at the State Administration of Traditional
Chinese Medicine of China.
Received: 13 January 2014 Accepted: 29 May 2014
Published: 5 June 2014References
1. Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D: Biomarkers for
anti-angiogenic therapy in cancer. Int J Mol Sci 2013, 14(5):9338–9364.
2. Tahergorabi Z, Khazaei M: A review on angiogenesis and its assays. Iranian
J Basic Med Sci 2012, 15(6):1110–1126.
3. Ng TB: Pharmacological activity of sanchi ginseng (Panax notoginseng).
J Pharm Pharmacol 2006, 58(8):1007–1019.
4. Chen H, Yin J, Deng Y, Yang M, Xu L, Teng F, Li D, Cheng Y, Liu S, Wang D,
Zhang T, Wu W, Liu X, Guan S, Jiang B, Guo D: The protective effects of
ginsenoside Rg1 against hypertension target-organ damage in
spontaneously hypertensive rats. BMC Compl Altern Med 2012, 12:53.
5. Leung KW, Wong AS: Pharmacology of ginsenosides: a literature review.
Chin Med 2010, 5:20.
6. Kim JH: Cardiovascular diseases and Panax ginseng: a review on
molecular mechanisms and medical applications. J Ginseng Res 2012,
36(1):16–26.
7. Hong SJ, Wan JB, Zhang Y, Hu G, Lin HC, Seto SW, Kwan YW, Lin ZX, Wang
YT, Lee SM: Angiogenic effect of saponin extract from Panax
notoginseng on HUVECs in vitro and zebrafish in vivo. Phytother Res: PTR
2009, 23(5):677–686.
8. Yu LC, Chen SC, Chang WC, Huang YC, Lin KM, Lai PH, Sung HW: Stability
of angiogenic agents, ginsenoside Rg1 and Re, isolated from Panax
ginseng: in vitro and in vivo studies. Int J Pharm 2007, 328(2):168–176.
9. Ohashi R, Yan S, Mu H, Chai H, Yao Q, Lin PH, Chen C: Effects of
homocysteine and ginsenoside Rb1 on endothelial proliferation and
superoxide anion production. J Surg Res 2006, 133(2):89–94.
10. Leung KW, Cheung LW, Pon YL, Wong RN, Mak NK, Fan TP, Au SC,
Tombran-Tink J, Wong AS: Ginsenoside Rb1 inhibits tube-like structure
formation of endothelial cells by regulating pigment epithelium-derived
factor through the oestrogen beta receptor. Br J Pharmacol 2007,
152(2):207–215.
11. Sun B, Xiao J, Sun XB, Wu Y: Notoginsenoside R1 attenuates cardiac
dysfunction in endotoxemic mice: an insight into oestrogen receptor
activation and PI3K/Akt signalling. Br J Pharmacol 2013, 168(7):1758–1770.
12. Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, Yeung
HW, Wong RN, Sasisekharan R, Fan TP: Modulating angiogenesis: the yin
and the yang in ginseng. Circulation 2004, 110(10):1219–1225.
13. He NW, Zhao Y, Guo L, Shang J, Yang XB: Antioxidant, antiproliferative,
and pro-apoptotic activities of a saponin extract derived from the roots
of Panax notoginseng (Burk.) F.H. Chen. J Med Food 2012, 15(4):350–359.
14. Wang P, Cui J, Du X, Yang Q, Jia C, Xiong M, Yu X, Li L, Wang W, Chen Y,
Zhang T: Panax notoginseng saponins (PNS) inhibits breast cancer
metastasis. J Ethnopharmacol 2014, 30(14):00320–00325.
15. Rona G, Chappel CI, Balazs T, Gaudry R: An infarct-like myocardial lesion
and other toxic manifestations produced by isoproterenol in the rat.
AMA Arch Pathol 1959, 67(4):443–455.
16. Rona G: Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985,
17(4):291–306.
17. Teerlink JR, Pfeffer JM, Pfeffer MA: Progressive ventricular remodeling in
response to diffuse isoproterenol-induced myocardial necrosis in rats.
Circ Res 1994, 75(1):105–113.
18. Zbinden G, Moe RA: Pharmacological studies on heart muscle lesions
induced by isoproterenol. Ann N Y Acad Sci 1969, 156(1):294–308.
Yang et al. BMC Complementary and Alternative Medicine 2014, 14:183 Page 9 of 9
http://www.biomedcentral.com/1472-6882/14/18319. Csapo Z, Dusek J, Rona G: Early alterations of the cardiac muscle cells in
isoproterenol-induced necrosis. Arch Pathol 1972, 93(4):356–365.
20. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R,
Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin
for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335–2342.
21. Sagar SM, Yance D, Wong RK: Natural health products that inhibit
angiogenesis: a potential source for investigational new agents to treat
cancer-Part 1. Curr Oncol 2006, 13(1):14–26.
22. Sagar SM, Yance D, Wong RK: Natural health products that inhibit
angiogenesis: a potential source for investigational new agents to treat
cancer-Part 2. Curr Oncol 2006, 13(3):99–107.
23. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S,
Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic microRNA
cluster, miR-17-92, is overexpressed in human lung cancers and
enhances cell proliferation. Cancer Res 2005, 65(21):9628–9632.
24. Wu W, Takanashi M, Borjigin N, Ohno SI, Fujita K, Hoshino S, Osaka Y,
Tsuchida A, Kuroda M: MicroRNA-18a modulates STAT3 activity through
negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J
Cancer 2013, 108(3):653–661.
25. Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A,
Morimura R, Tsujiura M, Nagata H, Kawaguchi T, Arita T, Kubota T, Fujiwara H,
Okamoto K, Otsuji E: Clinical impact of circulating miR-18a in plasma of
patients with oesophageal squamous cell carcinoma. Br J Cancer 2013,
108(9):1822–1829.
26. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C,
Schellings MW, Swinnen M, Cleutjens JP, van Zandvoort MA, Heymans S,
Schroen B: MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1
expression in age-related heart failure. Aging Cell 2011, 10(5):769–779.
27. Ohgawara T, Kubota S, Kawaki H, Kondo S, Eguchi T, Kurio N, Aoyama E,
Sasaki A, Takigawa M: Regulation of chondrocytic phenotype by micro
RNA 18a: involvement of Ccn2/Ctgf as a major target gene. FEBS Lett
2009, 583(6):1006–1010.
doi:10.1186/1472-6882-14-183
Cite this article as: Yang et al.: Bidirectional regulation of angiogenesis
and miR-18a expression by PNS in the mouse model of tumor
complicated by myocardial ischemia. BMC Complementary and Alternative
Medicine 2014 14:183.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
